Aravind Ravi Kumar

Long term follow-up and outcomes of re-treatment in an expanded 50 patient single-center phase II prospective trial of Lutetium-177 (177Lu) PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.

John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Sue Ping Thang, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, David A Pattison, Alexis Beaulieu, Jennifer Mooi, Christina Guo, Victor Kalff, Declan G Murphy, Price Jackson, Peter Eu, Mark Scalzo, Scott Williams, Rod J Hicks, Michael S Hofman

Journal article  |  2019  |  Journal of Nuclear Medicine

Objectives: Lutetium-177 (177Lu)-PSMA-617 (LuPSMA) is a radioligand with high affinity for prostate specific membrane antigen (PSM..

Setting the stage: Contemporary staging of non-melanomatous skin cancer and implementation of the new American Joint Committee on cancer eighth edition staging manual

Georgina Casswell, Karda Cavanagh, Aravind S Ravi Kumar, Charles Giddings, Lachlan McDowell

Journal article  |  2019  |  Oral Oncology

Non-melanomatous skin cancer (NMSC) generally refers to basal cell and squamous cell carcinoma of the skin. The majority of patien..

The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma

Grace Kong, Tess Schenberg, Christopher J Yates, Alison Trainer, Nirupa Sachithanandan, Amir Iravani, Aravind Ravi Kumar, Michael S Hofman, Tim Akhurst, Michael Michael, Rodney J Hicks

Journal article  |  2019  |  The Journal of Clinical Endocrinology & Metabolism

Purpose: Germline succinate dehydrogenase (SDHx) mutation carriers, especially SDHB, are at increased risk for malignancy and requ..

Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol

Amir Iravani, Benjamin Solomon, David A Pattison, Price Jackson, Aravind Ravi Kumar, Grace Kong, Michael S Hofman, Tim Akhurst, Rodney J Hicks

Journal article  |  2019  |  Thyroid

Background: Some patients with metastatic differentiated thyroid cancer (DTC) lack iodine avidity and are the..

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy

Sue Ping Thang, John Violet, Shahneen Sandhu, Amir Iravani, Tim Akhurst, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Scott G Williams, Rodney J Hicks, Michael S Hofman

Journal article  |  2019  |  European Urology Oncology

BACKGROUND: Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic castration-resistant prostate cancer (mCRPC) ..

Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series

Isaac Goncalves, Kate Burbury, Michael Michael, Amir Iravani, Aravind S Ravi Kumar, Tim Akhurst, Ing S Tiong, Piers Blombery, Michael S Hofman, David Westerman, Rodney J Hicks, Grace Kong

Journal article  |  2019  |  European Journal of Nuclear Medicine and Molecular Imaging

Efficacy of peptide receptor radionuclide therapy for esthesioneuroblastoma, the Peter MacCallum Cancer Centre experience

Olfat Kamel Hasan, Grace Kong, Aravind RaviKumar, Rodney Hicks

Conference Proceedings  |  2019  |  JOURNAL OF NUCLEAR MEDICINE

Dosimetry of Lu-177-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes

John Violet, Price Jackson, Justin Ferdinandus, Shahneen Sandhu, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Sue Ping Thang, Peter Eu, Mark Scalzo, Declan Murphy, Scott Williams, Rodney J Hicks, Michael S Hofman

Journal article  |  2019  |  Journal of Nuclear Medicine

WELL-DIFFERENTIATED NEUROENDOCRINE NEOPLASM (NEN) WITH NO OR LOW (68)GA-DOTATATE AND F-18-FDG-AVIDITY: AN UNDER-RECOGNISED MOLECULAR IMAGING PHENOTYPE AND POTENTIAL MIMICKING PITFALLS

L Zidan, T Hung, G Kong, T Akhurst, A Ravikumar, M Hofman, R Hicks, A Iravani

Conference Proceedings  |  2019  |  INTERNAL MEDICINE JOURNAL

Results of a 50 patient single-center phase II prospective trial of Lutetium-177 PSMA-617 theranostics in metastatic castrate-resistant prostate cancer.

Michael Hofman, John A Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Timothy J Akhurst, Jennifer Mooi, Christina Guo, Ben Tran, Price Jackson, Mark Scalzo, Peter Eu, Scott Williams, Shahneen Kaur Sandhu

Conference Proceedings  |  2019  |  Journal of Clinical Oncology

Characteristics and Outcomes of Therapy-Related Myeloid Neoplasms after Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Neuroendocrine Neoplasm (NEN): A Single Centre Series

I Goncalves, K Burbury, D Westerman, P Blombery, IS Tiong, A Iravani, A Ravikumar, M Michael, M Hofman, T Akhurst, R Hicks, G Kong

Conference Proceedings  |  2019  |  NEUROENDOCRINOLOGY

Induction PRRT With CAPTEM Chemotherapy in a High-risk Population of Metastatic Neuroendocrine Neoplasia (NEN): Balancing Efficacy With Risk

AS Ravi Kumar, J Ferdinandus, J Callahan, T Akhurst, MS Hofman, A Iravani, G Kong, M Michael, RJ Hicks

Conference Proceedings  |  2018  |  EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

[Lu-177]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S Hofman, John Violet, Rodney J Hicks, Justin Ferdinandus, Sue Ping Thang, Tim Akhurst, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Declan G Murphy, Peter Eu, Price Jackson, Mark Scalzo, Scott G Williams, Shahneen Sandhu

Journal article  |  2018  |  The Lancet Oncology

Preoperative Positron Emission Tomography for Node-Positive Head and Neck Cutaneous Squamous Cell Carcinoma

Nir Hirshoren, Elizabeth Olayos, Alan Herschtal, Aravind S Ravi Kumar, David E Gyorki

Journal article  |  2018  |  Otolaryngology–Head and Neck Surgery